AI drug discovery: what’s funding like now?

Building a startup or looking for your next investment in AI in drug discovery? Our report gives you the full picture.
Summary
AI in drug discovery funding is much stronger now, especially for companies that have already raised money. The last 12 months brought 91 deals and at least $7.6B, led by Isomorphic Labs and its $2.1B Series B.
That compares with 78 deals and at least $3.6B in the 12 months before. More money is going into more companies, although the checks have grown far faster than the deal count.
The giant rounds explain much of that gap. Take them out, and funding still grows, but at a pace that looks far less extraordinary.
More startups are getting funded, too. Yet first financings make up a smaller share of the deals. The market is growing without becoming much easier to enter.
Small rounds are harder to find in the completed deals. Meanwhile, a higher share of checks goes to companies raising later-stage capital.
Investors haven't lost interest. We counted more individual investors and more lead investors, which suggests the market has a broader base than the biggest headlines imply.
Isomorphic Labs, Chai Discovery and Enveda Biosciences show what they are paying for: powerful molecular models, pharmaceutical customers and medicines moving through development.
The money is going into different kinds of discovery. Protein design has attracted more deals, while generative small-molecule design still receives the most disclosed capital.
The United States remains the biggest funding market. China's deal count has climbed sharply, and a UK company still accounts for the biggest round.
We see a healthier market with a tougher divide between newcomers and well-funded teams. Investors are placing larger bets on AI drug discovery, but clinical results will decide how good those bets were.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

In our report covering the AI drug discovery market, you will always find fresh funding data, taken straight from our own verified funding database.
All funding deals in the AI drug discovery market over the last 24 months
Below is the table listing all the deals. You can find our methodology at the end of this page.
If you want a deeper understanding of the market and its current dynamics, get our AI drug discovery market report.
| Company | Category | Date | Stage | Deal size | What they do | Region | Lead investors | Country | Rank |
|---|---|---|---|---|---|---|---|---|---|
| Orakl Oncology | AI Phenotypic & Functional Screening | November 2026 | Series A | $34M | Combines AI with patient-derived tumor organoid screens to select preclinical oncology drugs and uncover biological co-targets. | Europe | Norrsken VC, Singular | France | |
| PsiThera | AI Hit Discovery & Lead Generation | November 2026 | Unknown | $25M | AI-designed medicines for difficult protein targets | North America | Not disclosed | United States | |
| SRTD biotech | AI Therapeutic Biologics / Protein Design | November 2026 | Seed | ~$36M | Uses AI-driven RNA-marker identification and construct design to generate cell-selective mRNA therapeutics. | Europe | Mérieux Equity Partners, NRW.BANK, Boehringer Ingelheim Venture Fund | Germany | |
| Sanyou Bio | AI Therapeutic Biologics / Protein Design | November 2026 | Series C | ~$15M | Runs AI-guided antibody discovery and engineering through its AI-STAL library and wet-lab/dry-lab drug-accelerator platform. | Asia-Pacific | Not disclosed | China | |
| Araceli Biosciences | AI Phenotypic & Functional Screening | November 2026 | Unknown | $4.5M | Provides AI-assisted high-content cellular imaging and phenotypic analysis for preclinical drug screening. | North America | Not disclosed | United States | |
| Venomics AI | AI Therapeutic Biologics / Protein Design | November 2026 | Seed | $2.7M | Uses AI and experimental screening of animal-venom peptides to identify and optimize therapeutic leads. | Asia-Pacific | Speciale Invest, South Park Commons | India | |
| Signet Therapeutics | AI Phenotypic & Functional Screening | November 2026 | Series A | $25M+ | Combines patient-derived organoid cancer models and AI to discover and preclinically validate targeted therapies. | Asia-Pacific | China Life Equity Investment | China | |
| Ribopeutic | AI Target & Causal Biology Discovery | October 2026 | Series A | Undisclosed | Uses AI to predict RNA structures and identify druggable RNA targets for small-molecule discovery. | Asia-Pacific | Loyal Valley Capital, Sinovation Ventures | China | |
| ALLOX | AI Hit Discovery & Lead Generation | October 2026 | Seed | $10M | Combines AI prediction and functional biophysical data to discover druggable allosteric sites and design small-molecule drug leads. | Europe | Asabys Partners | Spain | |
| Atlas Bio | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Seed | $10M | Uses a human-transcriptomics foundation model to predict drug-response biology and select preclinical development paths without animal trials. | Europe | Creandum | Switzerland | |
| Pathos AI | AI Target & Causal Biology Discovery | October 2026 | Series D+ | $237M | Uses agentic AI and human disease data to identify therapeutic assets, test disease-biology hypotheses and guide oncology drug development. | North America | Bristol Myers Squibb | United States | |
| Zhichong Pharma | Generative Small-Molecule Design | October 2026 | Series A | Undisclosed | Uses AI models to design therapeutic molecules for veterinary drug discovery and preclinical development. | Asia-Pacific | Tianhui Capital | China | |
| Warp Sciences | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Series A | $215M | Runs AI- and robotics-assisted medicinal chemistry labs that synthesize and test compound analogues during preclinical lead optimization. | North America | Lightspeed Venture Partners | United States | |
| Model Medicines | Generative Small-Molecule Design | October 2026 | Unknown | $5.1M | AI-designed drugs for infectious diseases | North America | Not disclosed | United States | |
| Undecimal Bio | AI Lead Optimization & Medicinal Chemistry | October 2026 | Seed | $18M | Uses AI and high-throughput biological screening to design ligand conjugates that deliver siRNA drug candidates beyond the liver. | Europe | 4BIO Capital, IQ Capital | United Kingdom | |
| LigIT | AI Therapeutic Biologics / Protein Design | October 2026 | Seed | Undisclosed | Uses generative AI to design novel peptide therapeutics and progress candidates from hits to preclinical leads. | Asia-Pacific | Not disclosed | China | |
| Rivercell | Preclinical Predictive AI & Autonomous DMTA | October 2026 | Seed | $25M | Builds AI virtual-cell models trained on experimental perturbation data to predict cellular drug response and toxicity before human trials. | Europe | HV Capital | France | |
| WhiteLab Genomics | AI Therapeutic Biologics / Protein Design | October 2026 | Series B | $26M | Uses AI models to design viral delivery vectors and programmable payloads for genomic therapeutics. | Europe | AVP | France | |
| Biossil | AI Repurposing / Indication Selection | September 2026 | Unknown | $153M | Uses AI to identify and redevelop previously abandoned drug candidates for new therapeutic applications. | North America | OpenAI Startup Fund | Canada | |
| HITS | AI Hit Discovery & Lead Generation | September 2026 | Series B | ~$13M | Offers HyperLab, an AI drug-discovery platform for virtual screening, lead design and preclinical molecular-property prediction. | Asia-Pacific | Premier Partners | South Korea | |
| BigHat Biosciences | AI Therapeutic Biologics / Protein Design | September 2026 | Series C | $75M | AI-driven antibody and protein engineering | North America | DFJ Growth, Premji Invest | United States | |
| Basecamp Research | AI Therapeutic Biologics / Protein Design | September 2026 | Series C | $140M | Biodiversity-trained AI protein design models | Europe | S32 | United Kingdom | |
| Big Picture Bio | AI Repurposing / Indication Selection | September 2026 | Seed | ~$2M | Uses generative world models to design and optimize preclinical cancer drug combinations and treatment sequences. | Europe | Kadmos Capital, Exceptional Ventures | United Kingdom | |
| Anew Labs | AI Therapeutic Biologics / Protein Design | September 2026 | Series A | $290M | AI designed therapeutic proteins and drugs | Asia-Pacific | HongShan, IDG Capital, Hillhouse Investment, 5Y Capital | China | |
| Mithrl | AI Target & Causal Biology Discovery | September 2026 | Series A | $20M | Develops an AI biomedical research platform that helps scientists identify therapeutic targets and evaluate disease mechanisms. | North America | Obvious Ventures | United States | |
| NUTSHELL Therapeutics | Generative Small-Molecule Design | September 2026 | Series C | Undisclosed | Uses an AI- and physics-based platform to design allosteric small-molecule therapeutics. | Asia-Pacific | Trustar Capital, Decheng Capital | China | |
| Moonwalk Biosciences | AI Target & Causal Biology Discovery | September 2026 | Series B | $70M | Epigenetic and RNAi therapeutic discovery | North America | Alpha Wave Global, YK Bioventures | United States | |
| Superluminal Medicines | Generative Small-Molecule Design | September 2026 | Series B | $60M | AI-designed GPCR-targeted medicines | North America | BVF Partners | United States | |
| AIPher | AI Hit Discovery & Lead Generation | September 2026 | Seed | $14M | AI platform for drug discovery | Asia-Pacific | Xiang He Capital | China | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | September 2026 | Series D+ | $311M | AI discovery of nature-derived medicines | North America | Catalio Capital Management | United States | |
| Axiom Therapeutics | AI Lead Optimization & Medicinal Chemistry | August 2026 | Unknown | $12M | AI-designed therapeutics for difficult drug targets | Europe | Not disclosed | United Kingdom | |
| Aureka Biotechnologies | Generative Small-Molecule Design | August 2026 | Series B | $100M | AI foundation models for therapeutics | North America | Granite Asia | United States | |
| Engine Biosciences | AI Target & Causal Biology Discovery | August 2026 | Series B | $5M | AI drug target discovery platform | Asia-Pacific | GV | Singapore | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | July 2026 | Series B | $5.8M | Automated AI-powered molecular synthesis | Europe | Not disclosed | United Kingdom | |
| Transcripta Bio | AI Repurposing / Indication Selection | July 2026 | Series A | $24M | AI-guided drug discovery platform | North America | Not disclosed | United States | |
| Sightera Biosciences | Generative Small-Molecule Design | July 2026 | Seed | ~$3.4M | AI-designed drugs from patient-derived biology | Europe | Entourage, Anacura, Qbic | Belgium | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | July 2026 | Series C | $400M | AI foundation models for molecular design | North America | Index Ventures | United States | |
| Drug Farm | AI Target & Causal Biology Discovery | July 2026 | Series D+ | $55M | AI-assisted immunology drug development | Asia-Pacific | Shanghai Pudong Leading Area Investment Center, Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise | China | |
| Alchemab Therapeutics | AI Therapeutic Biologics / Protein Design | July 2026 | Series A | $32M | AI-enabled protective antibody drug discovery | Europe | British Business Bank | United Kingdom | |
| MindRank AI | AI Lead Optimization & Medicinal Chemistry | July 2026 | Series B | $52M | AI-native clinical drug development | Asia-Pacific | Not disclosed | China | |
| LifeMine Therapeutics | AI Hit Discovery & Lead Generation | July 2026 | Series D+ | $188M | Fungal-derived therapeutic drug discovery | North America | Milky Way Investments | United States | |
| Integrated Biosciences | AI Hit Discovery & Lead Generation | July 2026 | Unknown | $68M | AI discovery of drugs targeting aging | North America | Not disclosed | United States | |
| Xellar Biosystems | Preclinical Predictive AI & Autonomous DMTA | June 2026 | Series A | $50M | AI-powered human cellular modeling | North America | Not disclosed | United States | |
| Graph Therapeutics | AI Target & Causal Biology Discovery | June 2026 | Seed | $5M | AI drug discovery for inflammatory diseases | Europe | Daphni | Austria | |
| Gero | AI Target & Causal Biology Discovery | June 2026 | Series B | $17M | AI discovery of drugs for aging diseases | Asia-Pacific | Not disclosed | Singapore | |
| NewLimit | AI Target & Causal Biology Discovery | June 2026 | Series C | $435M | Develops epigenetic rejuvenation medicines | North America | Founders Fund | United States | |
| Protuoso Biosciences | AI Therapeutic Biologics / Protein Design | May 2026 | Seed | $9.5M | Engineered multifunctional proteins for therapeutic drugs | North America | Taya Venture, Darwin Ventures | United States | |
| 20n Bio | AI Hit Discovery & Lead Generation | May 2026 | Seed | $7.5M | AI-designed protein therapeutics | North America | Not disclosed | United States | |
| Isomorphic Labs | Generative Small-Molecule Design | May 2026 | Series B | $2.1B | AI discovery and design of medicines | Europe | Thrive Capital | United Kingdom | |
| Galux | AI Therapeutic Biologics / Protein Design | May 2026 | Growth Equity | ~$1.4M | AI-driven protein and antibody design | Asia-Pacific | Not disclosed | South Korea | |
| Genesis Molecular AI | Generative Small-Molecule Design | May 2026 | Unknown | $40M | AI-designed small-molecule therapeutics | North America | Incyte | United States | |
| Stoked Bio | AI Hit Discovery & Lead Generation | May 2026 | Seed | Undisclosed | Therapies targeting drug-resistant diseases | North America | Not disclosed | Canada | |
| ALP Bio | Preclinical Predictive AI & Autonomous DMTA | April 2026 | Seed | $2.2M | AI drug discovery for protein therapeutics | Europe | 42CAP | Switzerland | |
| Aureka Biotechnologies | Generative Small-Molecule Design | April 2026 | Series A | $35M | AI foundation models for therapeutics | North America | HongShan | United States | |
| Fathom Therapeutics | Generative Small-Molecule Design | April 2026 | Series A | $47M | AI and physics-based molecule design | North America | Sutter Hill Ventures | United States | |
| 10x Science | Preclinical Predictive AI & Autonomous DMTA | April 2026 | Seed | $4.8M | AI platform for drug discovery | North America | Initialized Capital | United States | |
| Biossil | AI Repurposing / Indication Selection | April 2026 | Unknown | $43M | Uses AI to identify and redevelop previously abandoned drug candidates for new therapeutic applications. | North America | Founders Fund, OpenAI | Canada | |
| Helical | AI Target & Causal Biology Discovery | April 2026 | Seed | $10M | Biological AI models for drug research | Europe | redalpine | United Kingdom | |
| Syneron Bio | AI Hit Discovery & Lead Generation | March 2026 | Series B | $150M | AI-powered macrocyclic peptide drug discovery | Asia-Pacific | Decheng Capital, CDH VGC | China | |
| RyboDyn | AI Target & Causal Biology Discovery | March 2026 | Seed | $10M | AI-designed ribosome-targeting therapeutics | North America | Not disclosed | United States | |
| Earendil Labs | AI Therapeutic Biologics / Protein Design | March 2026 | Unknown | $787M | AI-driven antibody and biologics development | North America | Not disclosed | United States | |
| Congruence Therapeutics | AI Hit Discovery & Lead Generation | March 2026 | Unknown | $40M | Computational therapies for protein misfolding | North America | Dimension, OrbiMed | Canada | |
| Peak Perform Innova | AI Hit Discovery & Lead Generation | March 2026 | Seed | Undisclosed | AI drug discovery for complex diseases | Asia-Pacific | Huagai Capital, BioTrack Capital | China | |
| Ternary Therapeutics | Generative Small-Molecule Design | March 2026 | Seed | ~$4.8M | AI-designed molecular glue therapeutics | Europe | Daphni | United Kingdom | |
| Numerion Labs | AI Hit Discovery & Lead Generation | March 2026 | Series D+ | $20M | AI-powered small molecule drug discovery | North America | Not disclosed | United States | |
| Antiverse | AI Therapeutic Biologics / Protein Design | March 2026 | Series A | $9.3M | AI designed therapeutic antibodies for drug targets | Europe | Soulmates Ventures | United Kingdom | |
| Tamarind Bio | AI Therapeutic Biologics / Protein Design | February 2026 | Series A | $12M | Cloud computational tools for biotech research | North America | Dimension Capital | United States | |
| Turbine | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Series B | $25M | Virtual cell simulation for drug discovery | Europe | Interactive Venture Partners | Hungary | |
| Peptris Technologies | Generative Small-Molecule Design | February 2026 | Series A | $7.7M | AI peptide drug discovery platform | Asia-Pacific | IAN Alpha Fund, Speciale Invest | India | |
| Pharmacelera | AI Hit Discovery & Lead Generation | February 2026 | Series A | $7.1M | AI molecular design for drug discovery | Europe | Heran Partners | Spain | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Series B | ~$500K | Automated AI-powered molecular synthesis | Europe | Zeon Corporation | United Kingdom | |
| Sable Bio | Preclinical Predictive AI & Autonomous DMTA | February 2026 | Seed | $3.8M | AI drug discovery for therapeutics | Europe | MMC Ventures | United Kingdom | |
| Galux | AI Therapeutic Biologics / Protein Design | February 2026 | Series B | $31M | AI-driven protein and antibody design | Asia-Pacific | Yuanta Investment | South Korea | |
| LabGenius | AI Therapeutic Biologics / Protein Design | February 2026 | Series B | Undisclosed | AI-directed therapeutic antibody engineering | Europe | Not disclosed | United Kingdom | |
| Proxima | Generative Small-Molecule Design | January 2026 | Seed | $80M | Designs protein-interaction targeting medicines | North America | DCVC | United States | |
| Converge Bio | AI Hit Discovery & Lead Generation | January 2026 | Series A | $25M | AI platform for drug discovery | Middle East | Bessemer Venture Partners | Israel | |
| Zenitar | AI Lead Optimization & Medicinal Chemistry | January 2026 | Series C | Undisclosed | AI-guided clinical-stage drug discovery | Asia-Pacific | Temasek, Qiming Venture Partners | China | |
| Boltz PBC | Generative Small-Molecule Design | January 2026 | Seed | $28M | AI models for biomolecular design | North America | Amplify Partners, Andreessen Horowitz, Zetta Venture Partners | United States | |
| Topos Bio | Generative Small-Molecule Design | January 2026 | Seed | $10M | AI models for drug discovery | North America | Boldstart Ventures, Threshold Ventures | United States | |
| Soley Therapeutics | AI Phenotypic & Functional Screening | January 2026 | Series C | $200M | AI-powered cellular stress drug discovery | North America | Surveyor Capital | United States | |
| Syneron Bio | AI Hit Discovery & Lead Generation | December 2025 | Series A | Undisclosed | AI-powered macrocyclic peptide drug discovery | Asia-Pacific | AstraZeneca, AZ-CICC Healthcare Investment Fund | China | |
| Phil Rivers Technology | AI Target & Causal Biology Discovery | December 2025 | Series A | $14M | Disease simulation for drug discovery | Asia-Pacific | CAS Investment | China | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | December 2025 | Series B | $130M | AI foundation models for molecular design | North America | General Catalyst, Oak HC/FT | United States | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | December 2025 | Series B | $1.4M | Automated AI-powered molecular synthesis | Europe | Not disclosed | United Kingdom | |
| PsiThera | AI Hit Discovery & Lead Generation | December 2025 | Series A | $48M | AI-designed medicines for difficult protein targets | North America | Samsara Biocapital, Lightstone Ventures | United States | |
| Relation Therapeutics | AI Target & Causal Biology Discovery | December 2025 | Seed | $26M | Discovers targets using multimodal biology | Europe | DCVC, NVIDIA, Magnetic Ventures | United Kingdom | |
| ChemLex | AI Hit Discovery & Lead Generation | December 2025 | Series A | $45M | AI chemistry platform for drug discovery | Asia-Pacific | Granite Asia | Singapore | |
| TRIANA Biomedicines | AI Hit Discovery & Lead Generation | December 2025 | Series B | $120M | Molecular glue targeted protein degradation | North America | Ascenta Capital, Bessemer Venture Partners | United States | |
| immunitoAI | AI Therapeutic Biologics / Protein Design | November 2025 | Series A | $6.1M | AI designed antibodies for therapeutic discovery | Asia-Pacific | Ashish Kacholia | India | |
| Profluent | Generative Small-Molecule Design | November 2025 | Series B | $106M | Designs proteins using generative AI | North America | Altimeter Capital, Bezos Expeditions | United States | |
| AI Proteins | AI Therapeutic Biologics / Protein Design | November 2025 | Series A | $42M | Designed miniprotein medicines for therapeutic targets | North America | Mission BioCapital, Santé Ventures | United States | |
| Tandem AI | AI Hit Discovery & Lead Generation | November 2025 | Series A | $22M | Integrated AI drug discovery services | North America | VCapital, KHK Fund | United States | |
| Scripta Therapeutics | AI Target & Causal Biology Discovery | November 2025 | Seed | $12M | AI drug discovery for gene regulation | Europe | Oxford Science Enterprises, Apollo Health Ventures | United Kingdom | |
| Arpeggio Biosciences | AI Target & Causal Biology Discovery | November 2025 | Unknown | $20M | Transcriptomics platform for drug discovery | North America | Not disclosed | United States | |
| Iambic Therapeutics | Generative Small-Molecule Design | November 2025 | Series B | $100M+ | AI-driven clinical drug development | North America | Not disclosed | United States | |
| Aureka Biotechnologies | Generative Small-Molecule Design | November 2025 | Series A | $23M | AI foundation models for therapeutics | North America | 5Y Capital, Qiming Venture Partners | United States | |
| LifeMine Therapeutics | AI Hit Discovery & Lead Generation | November 2025 | Series D+ | $75M | Fungal-derived therapeutic drug discovery | North America | Not disclosed | United States | |
| Expedition Medicines | Generative Small-Molecule Design | October 2025 | Series A | $50M | AI-designed small molecule medicines | North America | Flagship Pioneering | United States | |
| NewLimit | AI Target & Causal Biology Discovery | October 2025 | Growth Equity | $45M | Develops epigenetic rejuvenation medicines | North America | Eli Lilly and Company | United States | |
| Peptilogics | AI Therapeutic Biologics / Protein Design | October 2025 | Series B | $78M | Engineers antimicrobial peptide therapeutics | North America | Presight Capital, Thiel Bio, Founders Fund | United States | |
| Bexorg | Preclinical Predictive AI & Autonomous DMTA | October 2025 | Series A | $23M | AI brain drug discovery platform | North America | Engine Ventures | United States | |
| Meta-Flux | Preclinical Predictive AI & Autonomous DMTA | October 2025 | Seed | $2M | Disease simulation for drug target discovery | Europe | Not disclosed | Ireland | |
| Tres Alchemix | Preclinical Predictive AI & Autonomous DMTA | September 2025 | Series A | $4.4M | AI-designed small molecule drug discovery | Asia-Pacific | DNX Ventures | Japan | |
| Manas AI | Generative Small-Molecule Design | September 2025 | Seed | $26M | AI-powered oncology drug discovery | North America | Not disclosed | United States | |
| DaltonTx | AI Lead Optimization & Medicinal Chemistry | September 2025 | Seed | $5.1M | AI decision engine for drug discovery | Europe | redalpine, IQ Capital Partners | United Kingdom | |
| Odyssey Therapeutics | AI Lead Optimization & Medicinal Chemistry | September 2025 | Series D+ | $213M | Develops precision autoimmune disease treatments | North America | Not disclosed | United States | |
| Alchemab Therapeutics | AI Therapeutic Biologics / Protein Design | September 2025 | Series A | $32M | AI-enabled protective antibody drug discovery | Europe | Not disclosed | United Kingdom | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | September 2025 | Series D+ | $150M | AI discovery of nature-derived medicines | North America | Premji Invest | United States | |
| Congruence Therapeutics | AI Hit Discovery & Lead Generation | September 2025 | Unknown | $32M | Computational therapies for protein misfolding | North America | Not disclosed | Canada | |
| CHARM Therapeutics | Generative Small-Molecule Design | September 2025 | Series B | $80M | AI-designed precision cancer therapeutics | Europe | New Enterprise Associates, SR One | United Kingdom | |
| Chemify | Preclinical Predictive AI & Autonomous DMTA | September 2025 | Series B | $51M+ | Automated AI-powered molecular synthesis | Europe | Wing Venture Capital, Insight Partners | United Kingdom | |
| Therna Biosciences | AI Therapeutic Biologics / Protein Design | August 2025 | Seed | $10M | Computational design of RNA medicines | North America | AIX Ventures, Pear VC, Fusion Fund | United States | |
| Sensorium Therapeutics | AI Hit Discovery & Lead Generation | August 2025 | Series A | $25M | AI-supported neuropsychiatric drug discovery | North America | Not disclosed | United States | |
| Tahoe Therapeutics | Preclinical Predictive AI & Autonomous DMTA | August 2025 | Series A | $30M | AI models trained on cellular data | North America | Amplify Partners | United States | |
| Ribopeutic | AI Target & Causal Biology Discovery | August 2025 | Seed | ~$14M | Uses AI to predict RNA structures and identify druggable RNA targets for small-molecule discovery. | Asia-Pacific | Tasly Capital, Panlin Capital | China | |
| Chai Discovery | AI Therapeutic Biologics / Protein Design | August 2025 | Series A | $70M | AI foundation models for molecular design | North America | Menlo Ventures | United States | |
| Zenitar | AI Lead Optimization & Medicinal Chemistry | August 2025 | Series B | Undisclosed | AI-guided clinical-stage drug discovery | Asia-Pacific | Qiming Venture Partners | China | |
| Synfini | AI Lead Optimization & Medicinal Chemistry | July 2025 | Seed | $8.9M | AI drug discovery and robotic lab | North America | JSL Health Capital | United States | |
| Healx | AI Repurposing / Indication Selection | July 2025 | Series C | $2M | AI-driven rare disease therapeutics | Europe | SCI Ventures | United Kingdom | |
| OutSee | AI Target & Causal Biology Discovery | June 2025 | Seed | $2.3M | AI platform for drug target discovery | Europe | Ahren Innovation Capital | United Kingdom | |
| Insilico Medicine | Generative Small-Molecule Design | June 2025 | Series D+ | $13M | AI-driven drug discovery and development | Asia-Pacific | Value Partners Group, Shanghai Pudong Venture Investment, Shanghai Pudong Development (Group), Wuxi Capital Group, Yixing State-owned Capital Investment Holding Group | Hong Kong | |
| Parallel Bio | Preclinical Predictive AI & Autonomous DMTA | June 2025 | Series A | $21M | Human immune models for drug discovery | North America | AIX Ventures | United States | |
| Kiin Bio | AI Hit Discovery & Lead Generation | June 2025 | Seed | $2.2M | AI designed small molecule therapeutics | Europe | b2venture | United Kingdom | |
| Ternary Therapeutics | Generative Small-Molecule Design | June 2025 | Seed | Undisclosed | AI-designed molecular glue therapeutics | Europe | Not disclosed | United Kingdom | |
| Vivodyne | Preclinical Predictive AI & Autonomous DMTA | May 2025 | Series A | $40M | Lab-grown human tissues for drug testing | North America | Khosla Ventures | United States | |
| ProteinQure | AI Therapeutic Biologics / Protein Design | May 2025 | Series A | $11M | AI designed peptide drugs for cancer | North America | Tom Williams / Heron Rock Fund | Canada | |
| iSiP | Generative Small-Molecule Design | May 2025 | Series A | ~$4.5M | AI drug discovery for novel compounds | Asia-Pacific | DNX Ventures | Japan | |
| Pathos AI | AI Target & Causal Biology Discovery | May 2025 | Series D+ | $365M | Uses agentic AI and human disease data to identify therapeutic assets, test disease-biology hypotheses and guide oncology drug development. | North America | Not disclosed | United States | |
| Inductive Bio | AI Lead Optimization & Medicinal Chemistry | May 2025 | Series A | $25M | AI drug discovery for small molecules | North America | Obvious Ventures | United States | |
| NewLimit | AI Target & Causal Biology Discovery | May 2025 | Series B | $130M | Develops epigenetic rejuvenation medicines | North America | Kleiner Perkins | United States | |
| Divamics | AI Lead Optimization & Medicinal Chemistry | May 2025 | Series A | Undisclosed | AI drug discovery and molecular design | Asia-Pacific | YuanBio Venture Capital | China | |
| Denovo Sciences | Generative Small-Molecule Design | May 2025 | Unknown | $1M | AI-designed small molecule drug candidates | Europe | Alchemist Doha | Armenia | |
| AMPLY Discovery | AI Target & Causal Biology Discovery | May 2025 | Seed | $1.8M | AI-designed therapeutics and antimicrobial discovery | Europe | Twin Path Ventures | United Kingdom | |
| Meddenovo Drug Design | Generative Small-Molecule Design | May 2025 | Seed | $450K | AI protein and drug design platform | Europe | Not disclosed | France | |
| Xellar Biosystems | Preclinical Predictive AI & Autonomous DMTA | April 2025 | Unknown | Undisclosed | AI-powered human cellular modeling | North America | XtalPi | United States | |
| Etiome | AI Target & Causal Biology Discovery | April 2025 | Unknown | $50M | AI drug discovery for preventive medicines | North America | Flagship Pioneering | United States | |
| Araceli Biosciences | AI Phenotypic & Functional Screening | April 2025 | Seed | $7.2M | Provides AI-assisted high-content cellular imaging and phenotypic analysis for preclinical drug screening. | North America | Not disclosed | United States | |
| BigHat Biosciences | AI Therapeutic Biologics / Protein Design | April 2025 | Series B | $44M | AI-driven antibody and protein engineering | North America | Not disclosed | United States | |
| Isomorphic Labs | Generative Small-Molecule Design | March 2025 | Series A | $600M | AI discovery and design of medicines | Europe | Thrive Capital | United Kingdom | |
| Olio Labs | AI Lead Optimization & Medicinal Chemistry | March 2025 | Seed | $4.5M | AI-designed multi-protein therapeutic drugs | North America | Boom Capital, Overwater Ventures | United States | |
| Arpeggio Biosciences | AI Target & Causal Biology Discovery | March 2025 | Unknown | $4M | Transcriptomics platform for drug discovery | North America | Not disclosed | United States | |
| Arbor Biotechnologies | AI Therapeutic Biologics / Protein Design | March 2025 | Series C | $74M | AI-assisted precision gene editing therapies | North America | ARCH Venture Partners, TCGX | United States | |
| Insilico Medicine | Generative Small-Molecule Design | March 2025 | Series D+ | $110M | AI-driven drug discovery and development | Asia-Pacific | Value Partners Group | Hong Kong | |
| Valo Health | AI Target & Causal Biology Discovery | March 2025 | Unknown | $21M | AI-driven computational drug development | North America | Indaco Venture Partners, CDP Venture Capital SGR | United States | |
| Alivexis | AI Lead Optimization & Medicinal Chemistry | March 2025 | Series D+ | $680K | Small-molecule therapies for difficult targets | Asia-Pacific | Not disclosed | Japan | |
| Eikon Therapeutics | AI Phenotypic & Functional Screening | February 2025 | Series D+ | $351M | Computational imaging-driven drug discovery | North America | Not disclosed | United States | |
| InVirtuoLabs | Generative Small-Molecule Design | February 2025 | Seed | $3.1M | AI drug discovery and molecular simulation | Europe | Not disclosed | Switzerland | |
| Achira | Preclinical Predictive AI & Autonomous DMTA | February 2025 | Seed | $33M | AI drug discovery for protein interactions | North America | Dimension | United States | |
| CircNova | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $3.3M | Generative design platform for RNA therapeutics | North America | South Loop Ventures | United States | |
| Variational AI | AI Hit Discovery & Lead Generation | February 2025 | Seed | $5.5M | AI-designed small molecule drug candidates | North America | Nimbus Synergies | Canada | |
| Latent Labs | AI Therapeutic Biologics / Protein Design | February 2025 | Series A | $40M | Generative AI protein design | Europe | Radical Ventures, Sofinnova Partners | United Kingdom | |
| Latent Labs | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $10M | Generative AI protein design | Europe | Pillar VC, Kindred Capital | United Kingdom | |
| Ordaos Bio | AI Therapeutic Biologics / Protein Design | February 2025 | Seed | $338K | Generative protein design for therapeutic discovery | North America | Not disclosed | United States | |
| Manas AI | Generative Small-Molecule Design | January 2025 | Seed | $25M | AI-powered oncology drug discovery | North America | General Catalyst, Reid Hoffman | United States | |
| RyboDyn | AI Target & Causal Biology Discovery | January 2025 | Seed | $4M | AI-designed ribosome-targeting therapeutics | North America | Genedant Capital, SeaX Ventures | United States | |
| Graph Therapeutics | AI Target & Causal Biology Discovery | January 2025 | Seed | $3.1M | AI drug discovery for inflammatory diseases | Europe | Squareone, Merantix Capital | Austria | |
| Pepticom | AI Therapeutic Biologics / Protein Design | January 2025 | Series A | $6.6M | AI peptide candidate discovery for therapeutics | Middle East | Japan Israel High Tech Ventures 2 LP | Israel | |
| Alivexis | AI Lead Optimization & Medicinal Chemistry | January 2025 | Series D+ | $5.4M | Small-molecule therapies for difficult targets | Asia-Pacific | JIC Venture Growth Investments | Japan | |
| Orbis Medicines | Generative Small-Molecule Design | January 2025 | Series A | $99M | AI designed oral macrocyclic drug candidates | Europe | New Enterprise Associates | Denmark | |
| DeepLife | AI Target & Causal Biology Discovery | December 2024 | Series A | $10M | Cell digital twins for drug discovery | Europe | YZR Capital, Relyens Innovation Santé | France | |
| Aqemia | Generative Small-Molecule Design | December 2024 | Series A | $38M | Physics-based generative AI drug discovery | Europe | Cathay Capital | France | |
| deepmirror | AI Lead Optimization & Medicinal Chemistry | December 2024 | Seed | $2.4M | Foundation models for molecular drug design | Europe | Twin Path Ventures | United Kingdom | |
| Orakl Oncology | AI Phenotypic & Functional Screening | December 2024 | Seed | Undisclosed | Combines AI with patient-derived tumor organoid screens to select preclinical oncology drugs and uncover biological co-targets. | Europe | Singular | France | |
| Cradle | AI Therapeutic Biologics / Protein Design | November 2024 | Series B | $73M | AI platform for protein engineering | Europe | IVP | Netherlands | |
| Enveda Biosciences | AI Hit Discovery & Lead Generation | November 2024 | Series C | $130M | AI discovery of nature-derived medicines | North America | Kinnevik, FPV | United States | |
| Aizen Therapeutics | AI Therapeutic Biologics / Protein Design | November 2024 | Seed | $13M | AI designed therapeutic peptides for immunology | North America | Madrona Venture Group | United States | |
| Modulo Bio | AI Target & Causal Biology Discovery | November 2024 | Unknown | $5.8M | Neuroimmune drug discovery platform | North America | Not disclosed | United States | |
| Converge Bio | AI Hit Discovery & Lead Generation | November 2024 | Seed | $5.5M | AI platform for drug discovery | Middle East | TLV Partners | Israel | |
| SRTD biotech | AI Therapeutic Biologics / Protein Design | November 2024 | Seed | Undisclosed | Uses AI-driven RNA-marker identification and construct design to generate cell-selective mRNA therapeutics. | Europe | High-Tech Gründerfonds | Germany |

In our research about AI drug discovery, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.
Is AI drug discovery funding actually booming right now?
Yes, AI drug discovery funding is growing quickly, and the increase extends beyond a few extraordinary checks.
We tracked 91 deals across 83 companies in the last 12 months, versus 78 deals across 71 companies in the 12 months before. The deals raised at least $7.6B, up 110% from at least $3.6B. Deal count and funded-company count both rose 17%. There's real growth here, although money is arriving much faster than new deals.
Look at the companies behind the larger checks. Isomorphic Labs raised a Series B in May 2026, Earendil Labs announced $787M across several financing rounds in March 2026, and NewLimit closed a $435M Series C in June 2026. These businesses can spend heavily on research, laboratories and their own therapeutic programs. A startup testing its first discovery model needs a very different check.
There is also steadier activity across the calendar: the median completed month had 8 deals in the latest period, compared with 6 previously. That makes the rebound broader than a single headline, even if the biggest rounds account for much of the dollar growth. The market is clearly busier. It hasn't become equally generous to everyone.
Would AI drug discovery funding still look good without the huge rounds?
AI drug discovery funding still grew without the giant rounds, but the increase was much less impressive.
Take out rounds above $50M and the last 12 months raised at least $1.1B, against at least $854M in the 12 months before, up 24%. Exclude rounds above $100M instead, and funding barely moves: at least $1.6B in both periods, a rise of just 4% once the exact amounts are compared. Both tests point to growth, but nowhere near the headline rise.
Isomorphic Labs shows why the gap is so wide. Its $600M Series A in March 2025 was the largest financing of the earlier period, followed by a $2.1B Series B in May 2026, the latest period's biggest deal. Chai Discovery's $400M Series C in July 2026 and Enveda Biosciences' $311M Series D+ round in September 2026 also moved the total substantially.
Those checks are genuine investments in drug research. Isomorphic is developing its own medicines alongside its design technology, while Enveda is spending on clinical work. But a founder trying to raise $10M won't necessarily recognize the market described by the headline total. Money is flowing more freely at the top than at the bottom.
Are more AI drug discovery startups getting funded, or just the same few?
More AI drug discovery startups are getting funded, even though a small set of repeat raisers gets much of the attention.
We counted 83 funded companies in the last 12 months, up from 71 in the 12 months before. Of those, 7 companies raised multiple rounds in the latest period, as many as in the 12 months before. The repeat-company rate slipped from 10% to 8%. The extra activity therefore isn't just the same businesses tapping investors again and again.
Chai Discovery appears twice in the recent financing history, yet counts as one company. Biossil raised $43M in April 2026 and $153M in September 2026, in two rounds of undisclosed stage. Warp Sciences and Rivercell, meanwhile, entered the picture with different approaches to combining computation and drug research.
There's an important split in the amounts. In the latest period, 76 companies completed a single round, 6 completed two rounds and 1 completed three. Follow-on financings still took most of the disclosed money. So the number of funded businesses is increasing, but the capital going to established teams is increasing much faster.
Can a brand-new AI drug discovery startup still get funded?
Yes, new AI drug discovery startups can get their first check today, although they receive a smaller share of the money.
We counted 17 first-financing deals totaling at least $640M in the last 12 months, versus 17 deals and at least $773M in the 12 months before. Their share of deals slipped from 22% to 19%. Their share of disclosed funding fell from 21% to 8%. About a fifth of the deals in each period could not be classified as a first or a later financing, so the true shares may be somewhat higher. For all the extra money entering the sector, its first-time recipients are getting a smaller part of it.
There are still striking exceptions. Boltz PBC raised a $28M Seed round in January 2026 to develop biomolecular models. Rivercell secured a $25M Seed round in October 2026 for virtual-cell research. Anew Labs raised a $290M Series A in September 2026 after ByteDance spun out its AI drugmaking unit, according to Reuters. That last example involved a business with substantial technology behind it, rather than a research team starting with nothing.
Most money now goes to follow-ons: 56 deals totaling at least $6.6B in the last 12 months, versus 44 deals and at least $2.6B previously. First-time founders can still persuade investors, but the fundraising boom is clearly more favorable to companies investors already know.
Are tiny AI drug discovery funding rounds disappearing?
Tiny AI drug discovery rounds haven't disappeared, but investors are completing fewer of them.
Among deals with public amounts, there were 11 rounds under $5M in the last 12 months, down from 18 in the 12 months before. Their share fell from 25% to 13%, while the disclosed capital in those rounds dropped from $46M to $31M. It is a real decline in completed small checks, not just a statistical effect of enormous Series B rounds.
Larger checks moved the other way. We found 24 deals from $5M to under $20M in the latest period, against 16 earlier. There were also 22 rounds from $20M to under $50M, versus 19 previously. Startups getting funded appear more likely to secure a meaningful research budget from the outset.
That leaves a difficult question for teams with one narrow scientific idea and little experimental evidence. Generating the first convincing data can require money long before a company has a drug candidate to show investors. The median age of companies raising under $5M fell from 3 years to 2 years, but we cannot see the startups that asked for capital and got turned down. Completed financings show a thinner entry point, not the size of the unfunded pipeline.

In our market report about AI drug discovery, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.
Are AI drug discovery investors writing bigger checks now?
Investors are writing larger checks for AI drug discovery, and the change goes beyond a single record round.
The median disclosed round climbed 20%, to $25.0M from $20.8M. Rounds of $100M or more increased from 9 deals to 17 deals, and their share of disclosed financings rose from 12% to 21%. These are sizable commitments for companies whose experimental results may still be years away from an approved drug.
Soley Therapeutics raised a $200M Series C in January 2026 for its oncology programs and cell-stress platform. Basecamp Research raised a $140M Series C in September 2026 to develop its EDEN models and AI-designed therapeutics. Chai Discovery also brought in a substantial later-stage financing for molecular design technology used by drugmakers.
A model vendor, an automated chemistry lab and a company running clinical trials aren't buying the same things with their funding. Trial programs can burn cash in a way a research-software business doesn't. The bigger median tells us what investors are actually funding today. It doesn't mean two similar startups would get better terms today than a year earlier.
Are AI drug discovery investors moving away from early-stage startups?
Later-stage AI drug discovery startups now take much more of the funding, even though early-stage checks continue.
Among deals with a named stage, early-stage rounds made up 59% in the last 12 months, compared with 70% in the 12 months before. The later-stage share rose from 30% to 41%. Series B alone reached 19 deals, up from 8, while Series C reached 8 deals versus 3. A lot more startups are raising the kind of money that supports work beyond an initial proof of concept.
The shift is bigger in dollars. Later-stage rounds received 80% of disclosed capital, against 60% previously. The early-stage share moved from 40% to 20%. Enveda Biosciences tied its September 2026 financing to expanding clinical studies and advancing additional drugs. Isomorphic Labs described plans to take its own candidates closer to the clinic.
The money is following businesses with research programs to finance, not simply ideas to test. That can be healthy for the companies moving toward medicines, but it leaves relatively less capital for early experiments.
The undisclosed-stage line ranks third because it includes Earendil Labs' $787M, which the company announced as several financing rounds without naming a stage. The table below shows the named stages and undisclosed-stage category, ordered by current disclosed capital.
| Stage | Deals now | Deals before | Capital now |
|---|---|---|---|
| Series B | 19 | 8 | $3.0B+ |
| Series C | 8 | 3 | $1.3B+ |
| Unknown | 10 | 8 | $1.2B |
| Series A | 23 | 21 | $987M+ |
| Series D+ | 5 | 9 | $811M |
| Seed | 25 | 28 | $324M+ |
| Growth Equity | 1 | 1 | $1.4M |
Are AI drug discovery startups raising money faster now?
Companies in AI drug discovery are raising their next rounds sooner, at least among financings we can date.
The median time between documented rounds fell from 22 months in the 12 months before to 17 months in the last 12 months. Of the measured gaps between consecutive rounds, 52% were under 18 months in the latest period, up from 41%. For gaps under 24 months, the share rose from 52% to 67%.
Those percentages describe gaps between rounds, not companies. Our timing analysis covered 64% of eligible gaps in the last 12 months and 59% in the 12 months before. Unpublished rounds could change the picture. Still, Chai Discovery offers a clear example of fast repeat fundraising: its $130M Series B in December 2025 was followed by a $400M Series C in July 2026.
Not every interval got shorter. The share of observed gaps under 12 months was 31% in the latest period, compared with 35% earlier. The middle of the fundraising cycle shortened, but there is no evidence that all AI drug discovery startups are suddenly raising every few months. Faster financing also tells us nothing by itself about faster clinical progress.
Are fewer investors willing to fund AI drug discovery?
No, AI drug discovery is attracting more investors, even while new startups struggle to claim a bigger share of their money.
We identified 173 unique investors in the last 12 months, compared with 108 in the 12 months before. The number of distinct disclosed lead investors increased from 76 to 97. We could identify a lead investor for 78% of recent deals, versus 74% earlier, so the longer list isn't just because more leads get named now.
The big names remain active. Thrive Capital led Isomorphic Labs' latest financing after leading its March 2025 round. Index Ventures led Chai Discovery's July 2026 Series C. Founders Fund led NewLimit's June 2026 Series C. These investors backed different ways of finding or developing drugs, from molecular models to medicines built around cell reprogramming.
There were 8 lead investors that led multiple rounds in the latest period, against 7 previously. But returning leads accounted for 23% of led deals, down from 24%. The investor base has become wider, while completed first financings have become less common. More money and more backers aren't automatically making the market easier for an unknown founder.
Why is Isomorphic Labs raising billions for AI drug discovery?
Isomorphic Labs is raising billions because investors are backing both its AI drug-design technology and its plans to develop medicines.
The company raised a $600M Series A in March 2025, followed by a $2.1B Series B in May 2026. Thrive Capital led both financings. Its latest round was the largest single AI drug discovery deal in the last 12 months, far beyond the checks usually available to an early-stage research team.
The company has announced collaborations with Eli Lilly, Novartis and Johnson & Johnson. In its January 2026 agreement with Johnson & Johnson, Isomorphic handles computer-based drug design while the pharmaceutical partner carries out experiments and development work. Isomorphic says the newer funding will support its IsoDDE system and advance its own medicines toward the clinic.
So investors aren't paying only for a promising model. They are financing a research platform, pharmaceutical relationships and a drug pipeline at once. The partnerships make the technology more credible than a laboratory demonstration alone, but the medicines still have to survive testing in patients. That last part remains the expensive, uncertain part of the bet.

Our document detailing everything you need to know about AI drug discovery gets updated several times a month, so you always get the latest view of where things stand.
Why do investors keep backing Chai Discovery?
Chai Discovery keeps attracting large checks because drugmakers are testing its AI-designed molecules in real laboratories.
The company raised $530M across 2 rounds in the last 12 months, including a $130M Series B in December 2025 and a $400M Series C in July 2026. Its molecular design models aim to help pharmaceutical teams create therapeutic proteins and other drug candidates.
One useful test came from GSK. In October 2026, Chai announced that GSK had evaluated its designs in the wet lab and found binders for every target tested. The companies then expanded their work together. Chai also announced relationships with Novartis and Pfizer. A drugmaker testing generated molecules is a stronger commercial sign than a startup publishing a model benchmark without a customer.
It still leaves plenty to prove. Finding a binder in the lab is not the same as showing a medicine is safe and effective in people. The revenue from design tools and research collaborations also works differently from revenue from selling approved drugs. Investors are betting that the laboratory results and partnerships can turn into a lasting business. We don't yet have enough evidence to treat that outcome as settled.
Does more AI drug discovery funding mean better medicines?
No, higher AI drug discovery funding does not mean the medicines are already better, safer or more likely to win approval.
The funding shows investors are willing to pay for the attempt. Enveda Biosciences has reported early clinical results from medicines identified through its discovery platform. Soley Therapeutics plans to advance oncology candidates after raising new capital. Those are meaningful steps, but neither a promising early readout nor a financing round settles what happens in larger trials.
There has been progress beyond computer predictions. In September 2026, Insilico Medicine announced that a first patient had received treatment in a Phase III study of rentosertib, a drug candidate linked to its generative-AI discovery methods. The company listed in Hong Kong in December 2025. Recursion, another listed developer, also reported that Sanofi had optioned a development candidate from their joint research.
Regulators still require evidence. The US Food and Drug Administration issued draft guidance in January 2025 on judging AI models used in drug regulatory decisions. The FDA and European Medicines Agency published shared AI principles in January 2026 covering data quality and performance testing. We can see more AI-linked programs moving through drug development, but we cannot yet say the sector has solved clinical failure.
Are drug companies really using AI discovery tools yet?
Yes, major drugmakers are testing AI drug discovery tools on real research problems, though the commercial results vary widely.
Isomorphic Labs' collaboration with Johnson & Johnson separates model-based design from the partner's experimental and drug-development work. Chai Discovery reported that GSK tested its generated designs before broadening their collaboration. Earendil Labs has described programs with Sanofi involving antibody medicines for inflammatory and autoimmune diseases. The partners are doing more than watching demonstrations.
Some companies are even building the research infrastructure themselves. In January 2026, Eli Lilly and NVIDIA announced a shared AI laboratory with plans to invest up to $1 billion over five years in research and infrastructure. That announcement isn't a startup financing and stays out of our totals, but it shows that a major pharmaceutical company wants to operate AI-enabled discovery rather than depend entirely on outside tools.
There is still a gap between a successful experiment and regular commercial use. Contracts can cover a narrow research task, and many candidate molecules never become medicines. What has changed is the kind of evidence available: actual wet-lab tests, partnered programs and candidates moving into development. That's stronger than hype, even if the eventual financial returns remain uncertain.
Are AI drug discovery investors now funding actual medicines?
Investors are funding AI drug discovery companies that develop their own medicines alongside businesses that sell models to drugmakers.
Earendil Labs announced $787M across several financing rounds in March 2026 for AI-assisted biologics research and a therapeutic pipeline. Enveda Biosciences raised $311M in a Series D+ round in September 2026, with its announcement tying the money to clinical work and its PRISM platform. NewLimit's $435M Series C in June 2026 backed medicines based on epigenetic reprogramming and its plans to begin human studies.
Basecamp Research is taking a similar combined approach. Its $140M Series C in September 2026 supported the EDEN model platform as well as AI-designed therapeutic programs. Each of these businesses needs to fund scientific work that may continue long after an initial molecule looks promising.
There is still room for another model. Chai Discovery develops technology used by drug companies, while automated-lab and prediction businesses can sell research capabilities. Both types of company attracted investors. The size of a round tells us how much work a team plans to finance, but it doesn't tell us which business model will end up earning more or producing better medicines.
Is AI protein design taking money away from small-molecule startups?
AI protein design hasn't overtaken small-molecule drug discovery in funding, even though more protein startups are getting checks.
The AI Therapeutic Biologics / Protein Design category recorded 20 deals raising at least $2.0B in the last 12 months, versus 15 deals and at least $465M in the 12 months before. Generative Small-Molecule Design recorded 16 deals in each period, while the money rose from at least $1.2B to at least $2.6B. Protein design is growing, and small-molecule design hasn't been pushed aside.
The companies aren't all solving the same problem. Chai Discovery builds models for molecular and protein design. Basecamp Research is using its biodiversity-trained models to design biological medicines. Isomorphic Labs is developing AI systems for therapeutic molecule discovery, while Fathom Therapeutics raised a $47M Series A in April 2026 for its AI- and physics-based small-molecule approach.
Investors are backing several kinds of molecules at the same time. The real division is between teams with useful scientific evidence and those still relying on model claims. There's no clear funding winner across every type of drug yet.
The table below shows the eight discovery categories, ordered by disclosed capital in the latest period.
| Category | Deals now | Deals before | Capital now |
|---|---|---|---|
| Small molecules | 16 | 16 | $2.6B+ |
| Protein design | 20 | 15 | $2.0B+ |
| Hit discovery | 19 | 9 | $1.1B+ |
| Target discovery | 13 | 15 | $904M+ |
| Predictive AI | 11 | 9 | $343M |
| Phenotypic screening | 4 | 3 | $264M+ |
| Repurposing | 4 | 1 | $222M |
| Lead optimization | 4 | 10 | $82M+ |

In our report covering the AI drug discovery market, we look at what the winners do differently, so you can learn from the best instead of guessing.
Is AI drug repurposing suddenly a big investment area?
Drug repurposing startups using AI are raising bigger checks, but the category remains small.
The AI Repurposing / Indication Selection category recorded 4 deals totaling $222M in the last 12 months, against 1 deal totaling $2M in the 12 months before. Its share of deals moved from 1% to 4%. The change looks dramatic because there was so little activity in the earlier period.
Biossil accounts for much of the story. The company raised $43M in April 2026 and $153M in September 2026, both in rounds of undisclosed stage. Its approach is to use AI to revisit drug candidates that companies previously stopped developing and look for a better use. Canadian law firm Osler said the September financing was entirely equity and supported further clinical development and selected asset acquisitions.
An abandoned candidate can bring useful existing research with it, but a new use still requires convincing clinical evidence. Other teams are also working on repurposing, yet the recent amounts leave the category heavily influenced by one company. Investors are interested, but a broad new wave of successful businesses has not been established.
Is China catching up with the US in AI drug discovery funding?
China is catching up in AI drug discovery deal activity, although American startups still raise far more capital.
Companies based in China completed 15 deals and raised at least $615M in the last 12 months. In the 12 months before, they completed 3 deals and raised at least $14M. China's share of deals rose from 4% to 16%. That is a sharp change in how often Chinese drug discovery startups appear in funded rounds.
Anew Labs raised a $290M Series A in September 2026 after being spun out of ByteDance. Reuters reported that ByteDance retained an ownership interest and that HongShan, IDG Capital and other investors backed the company. Syneron Bio raised a $150M Series B in March 2026 for peptide discovery, while MindRank AI raised a $52M Series B in July 2026 for AI-guided medicinal chemistry. The increase covers different kinds of drug research, not only one spinout.
The US still leads in both deal count and disclosed capital. What has changed is how much of the market investors would miss by looking only at American companies. China is now an important part of the current funding story.
Is the US losing its grip on AI drug discovery funding?
No, the United States still leads AI drug discovery funding, even though other countries are doing more deals.
US companies raised at least $4.0B across 36 deals in the last 12 months, versus at least $2.3B across 39 deals in the 12 months before. Their share of deals went from 50% to 40%, while their share of disclosed capital moved from 64% to 53%. The deal count slipped slightly, but the money increased substantially.
American businesses such as Chai Discovery, NewLimit and Enveda Biosciences still attract very large financings. At the same time, Isomorphic Labs accounts for a huge UK round, and more Chinese companies are receiving checks. This is less a retreat by US investors than an expansion of funded activity elsewhere.
The United Kingdom remains an important market too, with 15 deals raising at least $2.4B in the last 12 months. That helps explain why the global total can jump even when the US completes fewer deals than before.
The table below shows countries with at least 3 deals in the latest period, ordered by disclosed capital.
| Country | Deals now | Capital now |
|---|---|---|
| United States | 36 | $4.0B |
| United Kingdom | 15 | $2.4B+ |
| China | 15 | $615M+ |
| Canada | 4 | $236M+ |
| France | 3 | $85M |
| Singapore | 3 | $67M |
| South Korea | 3 | $46M |
| India | 3 | $16M |
Can automated AI drug discovery labs really attract big funding?
Yes, automated AI drug discovery labs can raise substantial capital, although investors also fund tools that predict biology without running physical experiments.
The Preclinical Predictive AI & Autonomous DMTA category recorded 11 deals totaling $343M in the last 12 months, compared with 9 deals and at least $204M in the 12 months before. The category's share of all deals stayed at 12% in each period, so the growth came from larger checks rather than many more rounds.
Warp Sciences raised a $215M Series A in October 2026. Bloomberg reported that the company, launched by former OpenAI science executive Kevin Weil and fellow researchers, wanted to speed up drug research with AI-assisted laboratory work. Xellar Biosystems announced $50M across its Series A and A+ rounds in June 2026 for AI-powered cellular models, while Rivercell's $25M Seed round in October 2026 supported virtual-cell simulations.
These companies approach the same research bottleneck differently. Some aim to run experiments more efficiently, while others try to predict which ones are worth running. That can save time if the predictions hold up in the lab. Funding proves that investors want these tools, but it cannot establish how much experimental work they actually save.
So, what does AI in drug discovery funding look like right now?
AI in drug discovery funding is healthier today, with more money and more funded companies, but the biggest benefits go to teams that have already proved something to investors.
The increase extends beyond a handful of giant rounds, although those rounds explain much of the dramatic rise in total capital. More investors are writing checks and more companies are raising money. The part that looks weaker is the first financing: new startups aren't sharing in the growth on equal terms.
The large rounds also tell us what investors want. Isomorphic Labs is building AI models and its own medicines. Chai Discovery has pharmaceutical partners testing its designs in wet labs. Enveda Biosciences is financing clinical programs. These are expensive businesses with different ways to make money, but all have work beyond a model demonstration.
There's still a long road from a designed molecule to an approved medicine. Investors are willing to finance that journey more aggressively now. The sector's next test is whether those increasingly well-funded projects can deliver drugs that work in patients.
The table below shows what we found.
| Question | Answer |
|---|---|
| Is the market growing beyond famous deals? | Yes, more AI drug discovery startups are raising money now. We counted 91 deals over the last 12 months. That wider activity makes the growth more convincing. |
| Does growth hold up without billion-dollar headlines? | It does, although the increase becomes much less dramatic. Capital excluding rounds above $50M rose 24% between periods. Ordinary funding improved far less than the headline total. |
| Are smaller drug discovery checks keeping pace? | No, smaller checks are growing much more slowly overall. Funding excluding rounds above $100M rose only 4%. Giant rounds still explain most of the excitement. |
| Can new founders share in the boom? | They can, but first financings now make up a smaller share of deals. Their share fell from 22% to 19% between periods. Existing teams receive a much larger share of funding. |
| Are the smallest research rounds drying up? | Yes, the tiniest completed rounds are losing ground. Deals under $5M fell from 18 to 11. That leaves fewer teams with the smallest reported checks. |
| Do repeat raisers now collect most money? | Yes, follow-on financing takes most AI drug discovery capital. Follow-ons represented 87% of disclosed capital in the latest period. Investors are rewarding companies they have funded before. |
| Are repeat financings arriving sooner these days? | Generally, yes, the measured interval between rounds has shortened. The median fell from 22 months to 17 months. That says nothing about whether drug research sped up. |
| Have investment firms stopped backing drug discovery? | No, the number of participating investors has increased. We identified 173 unique investors in the latest period. A broader investor base still favors established companies. |
| Has protein design overtaken small-molecule drug discovery? | Not in disclosed capital, despite greater interest in proteins. Protein design recorded 20 deals in the latest period. Small-molecule design still attracted the larger funding amount. |
| Is China's funding rise challenging American dominance? | China is becoming more active but remains behind America. Chinese startups completed 15 deals in the latest period. US companies still attracted much more disclosed capital. |
| Do record checks prove AI-designed medicines work? | No, financing cannot establish whether a medicine will succeed. Insilico Medicine entered Phase III dosing in September 2026. Clinical results will ultimately test whether those expectations make sense. |

In our research about AI drug discovery, we don't want to repeat what boring consulting reports say. Instead, we show you the real and latest market signals that matter.
Our methodology
Our data runs through November 13, 2026. We compared the last 12 months (November 14, 2025 to November 13, 2026) with the 12 months before (November 14, 2024 to November 13, 2025). Both periods are within our complete deal coverage beginning in January 2024. The comparison contains enough transactions in each period to use the same 12-month length rather than extend the window.
We include private-company equity financings of at least $300K. We exclude debt, grants, loans, unconverted convertibles, SAFEs and public offerings. We count every qualifying financing once, consolidate duplicates of the same announcement and keep distinct rounds separate. Undisclosed deal amounts count toward the number of financings but not disclosed-dollar totals, so some capital totals are expressed as minimums.
We define AI in drug discovery as the use of AI to identify biological targets, find or design therapeutic molecules, optimize candidates, repurpose drugs, or test preclinical predictions in a repeatable discovery workflow. Companies selling discovery software, research services, partnered programs or their own medicines can qualify. We include borderline companies with a real preclinical discovery product rather than excluding them because that work is not their sole business. We exclude diagnostics-only, clinical operations, regulatory workflow, manufacturing-only and general-purpose AI businesses without evidenced drug-discovery activity.
Every company counted meets our startup definition: independent, founded in 2000 or later, technology-led and designed for rapid growth, financed privately or by its founders, and not publicly listed for more than five years. Recently acquired companies can remain within the stated eligibility window. We assign categories by primary discovery activity and geography by headquarters country. Stage groups distinguish Seed and Series A from Series B and later, while unknown stages remain separate rather than being guessed.
We prioritize company announcements, regulatory filings and reliable reporting.
Rounds confirmed by a company announcement, a press article or a regulatory filing are counted in full. Where no article exists, a round is counted only when at least two recognised databases agree on its date (within one month) and amount (within 5%), and it is marked as low confidence; a round found in a single database stays in the company's history but is left out of totals. For companies that have raised more than $100M, every round counted is backed by an article.
We distinguish the amount announced in a deal from a company's lifetime funding or any undisclosed investor check. Investor names are used when an identifiable lead or participant is reported. We calculate deal counts, company breadth, stage shares, disclosed capital and repeat-round intervals on their relevant recorded bases; financing velocity refers to documented gaps between rounds, not the percentage of companies that raise again.
A published total may differ from a broader press estimate because another source includes debt, grants, public financings, transactions below our threshold or companies outside our market definition. A weak partial month is not evidence of a sector collapse, and unknown amounts never become invented zero-dollar deals. These rules make the two consecutive periods comparable rather than forcing them to match every outside headline.
Key sources include Isomorphic Labs' May 2026 Series B, lead investor and research plans, Isomorphic Labs' March 2025 external financing, Johnson & Johnson's January 2026 Isomorphic Labs collaboration, Chai Discovery's July 2026 Series C and molecular design strategy, Chai Discovery's GSK wet-lab evaluation and October 2026 agreement, Enveda's September 2026 Series E and clinical progress, Earendil Labs' March 2026 financing announcement and Sanofi partnerships, NewLimit's June 2026 Series C and therapeutic-development plans, Reuters on Anew Labs, its financing and ByteDance separation, Basecamp Research's September 2026 Series C and EDEN program, Soley Therapeutics' January 2026 Series C and oncology pipeline, Biossil's September 2026 all-equity financing and drug-repurposing model, Warp Sciences' October 2026 launch and financing, FDA draft guidance on AI credibility in drug development, FDA and EMA January 2026 AI principles for medicine development, Insilico Medicine's September 2026 Phase III first patient, Recursion's clinical and partnered discovery updates, and Eli Lilly and NVIDIA co-innovation laboratory announcement.

Learning from others' mistakes is the cheapest lesson there is. In our market report about AI drug discovery, we look at what broke startups before you, so you don't repeat it.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
